English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The potential benefit of probiotics on the gut microbiota and on various gastrointestinal disorders is well documented. It has become clear that these probiotic effects are strain-specific, underlying the necessity for a well-founded strain selection for research and clinical practice. Whether probiotics also have a positive effect on parameters of gastrointestinal function in a healthy population is less investigated. The objective of this in vivo observational study was to investigate the effect of a 6-week intervention with a multispecies probiotic product on gut health and quality of life (QoL) in a population of otherwise healthy adults and to evaluate the feasibility of conducting a controlled trial on probiotic effects in this population. A total of 40 participants from 3 different health centres were included in the study. After a 1-week inclusion phase, participants were supplemented for a 6-week period with Winclove 500/BactoSan pro FOS. During the run-in phase and each week during the observational period, gastrointestinal functional parameters were documented by an adapted version of the Eypasch questionnaire. Data on QoL was collected at baseline and at the end of the intervention period. The total gastrointestinal (GI) symptom score was reduced from 10 (4 - 21) at baseline to 6 (0 - 15) (p

advances in microbiology

Use of the Multispecies Probiotic Winclove 500/BactoSan pro FOS Leads to Less Gastrointestinal Complaints in Adults—An Observational &amp;lt;i&amp;gt;In Vivo&amp;lt;/i&amp;gt; Pilot Study